We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEX (IEX) Authorizes Share Repurchase Program Worth $500M
Read MoreHide Full Article
IDEX Corporation (IEX - Free Report) recently announced that its board has approved an additional share repurchase program, authorizing it to buy back up to $500 million of its shares.
Under this program, the company is likely to make share repurchases from time to time through several means that include open market transactions and privately negotiated transactions. The timing and amount of share repurchases will depend on certain factors such as market conditions and relevant securities laws.
Strong cash flows allow IDEX to effectively deploy capital for repurchasing shares, paying out dividend as well as making acquisitions. Notably, the company’s free cash flow recorded an increase of 12.7% to $477.2 million in 2019, on a year-over-year basis. In 2019, the company repurchased shares worth $54.7 million and distributed dividends totaling $147.2 million. The quarterly dividend rate currently stands at 50 cents per share (a hike of 16% was announced in May 2019). As a matter of fact, this share repurchase program is likely to instill confidence among investors.
Existing Business Scenario
IDEX expects industrial markets to remain challenging in the first half of 2020, on account of weak global demand for industrial products. Notably, it expects organic sales for the year to be down 2% to flat. In the first quarter of 2020, the company anticipates organic sales to decline in the range of 4-5%.
Also, the company’s international operations have exposed it to the adverse impacts of macroeconomic cycles in the United States and international markets. Also, it faces risk from unfavorable movements in foreign currencies. For instance, in the fourth quarter of 2019, forex woes had an adverse 1% impact on its sales.
In the past six months, the Zacks Rank #4 (Sell) company's shares have dipped 30.6%, wider than the industry’s decline of 17.5%. Also, analysts have become increasingly bearish about the company in the past seven days. Consequently, the Zacks Consensus Estimate for its 2020 earnings has trended downward from $5.74 to $5.65 on two downward estimate revisions versus none upward. Over the same time frame, the consensus estimate for 2021 earnings has been revised downward from $6.14 to $6.07.
Graco delivered positive earnings surprise of 0.40%, on average, in the trailing four quarters.
Tennant delivered positive earnings surprise of 26.60%, on average, in the trailing four quarters.
Broadwind Energy delivered positive earnings surprise of 10.42%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
IDEX (IEX) Authorizes Share Repurchase Program Worth $500M
IDEX Corporation (IEX - Free Report) recently announced that its board has approved an additional share repurchase program, authorizing it to buy back up to $500 million of its shares.
Under this program, the company is likely to make share repurchases from time to time through several means that include open market transactions and privately negotiated transactions. The timing and amount of share repurchases will depend on certain factors such as market conditions and relevant securities laws.
Strong cash flows allow IDEX to effectively deploy capital for repurchasing shares, paying out dividend as well as making acquisitions. Notably, the company’s free cash flow recorded an increase of 12.7% to $477.2 million in 2019, on a year-over-year basis. In 2019, the company repurchased shares worth $54.7 million and distributed dividends totaling $147.2 million. The quarterly dividend rate currently stands at 50 cents per share (a hike of 16% was announced in May 2019). As a matter of fact, this share repurchase program is likely to instill confidence among investors.
Existing Business Scenario
IDEX expects industrial markets to remain challenging in the first half of 2020, on account of weak global demand for industrial products. Notably, it expects organic sales for the year to be down 2% to flat. In the first quarter of 2020, the company anticipates organic sales to decline in the range of 4-5%.
Also, the company’s international operations have exposed it to the adverse impacts of macroeconomic cycles in the United States and international markets. Also, it faces risk from unfavorable movements in foreign currencies. For instance, in the fourth quarter of 2019, forex woes had an adverse 1% impact on its sales.
In the past six months, the Zacks Rank #4 (Sell) company's shares have dipped 30.6%, wider than the industry’s decline of 17.5%. Also, analysts have become increasingly bearish about the company in the past seven days. Consequently, the Zacks Consensus Estimate for its 2020 earnings has trended downward from $5.74 to $5.65 on two downward estimate revisions versus none upward. Over the same time frame, the consensus estimate for 2021 earnings has been revised downward from $6.14 to $6.07.
Stocks to Consider
Some better-ranked stocks from the same space are Graco Inc. (GGG - Free Report) , Tennant Company (TNC - Free Report) and Broadwind Energy, Inc. (BWEN - Free Report) . While Graco and Tennant sport a Zacks Rank #1 (Strong Buy), Broadwind Energy carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Graco delivered positive earnings surprise of 0.40%, on average, in the trailing four quarters.
Tennant delivered positive earnings surprise of 26.60%, on average, in the trailing four quarters.
Broadwind Energy delivered positive earnings surprise of 10.42%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>